| Dr Bradley Allen Wilson, MD | |
|
500 E Robinson Suite 1300, Norman Urology Associates, Pc, Norman, OK 73071-6694 | |
| (405) 360-9966 | |
| (405) 360-9905 |
| Full Name | Dr Bradley Allen Wilson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 15 Years |
| Location | 500 E Robinson Suite 1300, Norman, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407084791 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 30538 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norman Regional | Norman, OK | Hospital |
| Grady Memorial Hospital | Chickasha, OK | Hospital |
| Community Hospital, Llc | Oklahoma city, OK | Hospital |
| Oklahoma Center For Orthopaedic & Multi-sp | Oklahoma city, OK | Hospital |
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Norman Urology Associates Pc | 6103888961 | 7 |
News Archive
Leading academic and professional publisher SAGE today announced the launch of a new online resource that will put the spotlight on research published across its scholarly journals.
A new model looking at diabetes prevalence in England has been developed which outlines detailed information on the number of people with diabetes in the UK.
Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).
BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.
› Verified 2 days ago
| Entity Name | Norman Urology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679645055 PECOS PAC ID: 6103888961 Enrollment ID: O20041103000406 |
News Archive
Leading academic and professional publisher SAGE today announced the launch of a new online resource that will put the spotlight on research published across its scholarly journals.
A new model looking at diabetes prevalence in England has been developed which outlines detailed information on the number of people with diabetes in the UK.
Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).
BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.
› Verified 2 days ago
| Entity Name | Oklahoma Proton Center Llc |
|---|---|
| Entity Type | Part B Supplier - Radiation Therapy Center |
| Entity Identifiers | NPI Number: 1114408762 PECOS PAC ID: 4183963861 Enrollment ID: O20190225000069 |
News Archive
Leading academic and professional publisher SAGE today announced the launch of a new online resource that will put the spotlight on research published across its scholarly journals.
A new model looking at diabetes prevalence in England has been developed which outlines detailed information on the number of people with diabetes in the UK.
Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).
BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradley Allen Wilson, MD 500 E Robinson Suite 1300, Norman Urology Associates, Pc, Norman, OK 73071-6694 Ph: (405) 360-9966 | Dr Bradley Allen Wilson, MD 500 E Robinson Suite 1300, Norman Urology Associates, Pc, Norman, OK 73071-6694 Ph: (405) 360-9966 |
News Archive
Leading academic and professional publisher SAGE today announced the launch of a new online resource that will put the spotlight on research published across its scholarly journals.
A new model looking at diabetes prevalence in England has been developed which outlines detailed information on the number of people with diabetes in the UK.
Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).
BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.
› Verified 2 days ago
Philip Lee Jones, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 500 E Robinson St, Suite 1300, Norman, OK 73071 Phone: 405-360-9966 Fax: 405-360-9905 | |
Samuel C Le, PA-C Urology Medicare: Medicare Enrolled Practice Location: 500 E Robinson St Ste 1300, Norman, OK 73071 Phone: 405-360-9966 Fax: 405-360-9905 | |
Glenroy Hines Jr., PA-C Urology Medicare: Accepting Medicare Assignments Practice Location: 500 E Robinson St, Ste 1300, Norman, OK 73071 Phone: 405-360-9966 Fax: 405-360-9905 | |
Samuel Edward Dakil Ii, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 500 E Robinson St, Suite 1300, Norman, OK 73071 Phone: 405-360-9966 Fax: 405-360-9905 | |
Clifton Louis Whitesell, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 500 E Robinson St, Suite 1300, Norman, OK 73071 Phone: 405-360-9966 Fax: 405-360-9905 |